Ethyol® (Amifostine) for Injection
An advanced cytoprotective agent designed to preserve healthy cells and reduce toxicities during specific oncology treatments.
Quick Indications
- Decreases cumulative renal toxicity from cisplatin in advanced ovarian cancer.
- Reduces severe xerostomia during post-operative radiation for head & neck cancer.
How Does Ethyol Protect Normal Cells?
Ethyol is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to its active metabolite, which acts as a potent scavenger of free radicals.
Renal Protection Profile
Helps safeguard delicate renal pathways against cumulative, heavy-dose chemotherapy agents.
View Patient Outcomes →Salivary Gland Defense
Maintains moisture levels and minimizes xerostomia incidence during active head and neck radiation.
See Clinical Trials →Dosing & Administration
Strict structural adherence to administration windows ensures maximum cellular optimization.
Read Dosing Matrix →Healthcare Professionals
Access comprehensive clinical support, clinical trial statistics, reconstruction data, and full storage configurations for Ethyol.
HCP ResourcesPatients & Caregivers
Understand your treatment plan, know what to expect during your Ethyol infusion, and find financial co-pay support documentation.
Patient GuideImportant Safety Information Regarding Ethyol
Contraindications: Ethyol should not be administered to patients with known hypersensitivity to aminothiol compounds.
Warnings and Precautions: Patients receiving Ethyol should be well hydrated prior to the infusion. Severe hypotension has been reported during administration. Blood pressure should be monitored closely.
View All Boxed Warnings & Adverse Reactions